About Natera
Natera is a company based in Redwood City (United States) founded in 2004. Natera has raised $152.1 million across 13 funding rounds from investors including Lightspeed Venture Partners, Franklin Templeton and HHS. The company has 4,430 employees as of December 31, 2024. Natera has completed 1 acquisition, including Foresight Diagnostics. Natera offers products and services including Signatera, Panorama, Prospera, Horizon, and Renasight. Natera operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Prenetics and Veracyte, among others.
- Headquarter Redwood City, United States
- Employees 4430 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Natera, Inc.
-
Annual Revenue
$1.7 B (USD)56.75as on Dec 31, 2024
-
Net Profit
-$190.43 M (USD)56.2as on Dec 31, 2024
-
EBITDA
-$191.33 M (USD)52.75as on Dec 31, 2024
-
Total Equity Funding
$152.1 M (USD)
in 13 rounds
-
Latest Funding Round
$287.5 M (USD), Post-IPO
Apr 13, 2020
-
Investors
Lightspeed Venture Partners
& 14 more
-
Employee Count
4430
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Natera
Natera is a publicly listed company on the NASDAQ with ticker symbol NTRA in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Natera
Natera offers a comprehensive portfolio of products and services, including Signatera, Panorama, Prospera, Horizon, and Renasight.
Detects residual disease in cancer patients through DNA analysis
Screens for genetic conditions in prenatal testing
Assesses transplant organ health via DNA monitoring
Provides carrier screening for genetic disorders
Evaluates kidney gene panels for health risks
People of Natera
Unlock access to complete
Unlock access to complete
Leadership Team
124 people
Software Development Team
90 people
Product Management Team
75 people
Senior Team
70 people
Sales and Marketing
66 people
Data Analysis and Operations Team
35 people
Clinical Team
33 people
Operations Team
22 people
Unlock access to complete
Funding Insights of Natera
Natera has successfully raised a total of $152.1M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $287.5 million completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Natera
Natera has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Franklin Templeton and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Natera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Natera
Natera has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Foresight Diagnostics.
Investment portfolio details for Natera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Minimally invasive liquid biopsy tests for cancer detection are developed.
|
Locked | Locked | 2020 | Locked |
Complete acquisition details for Natera
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Natera
Detailed financials for Natera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Natera Comparisons
Peer comparison for Natera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Natera
Natera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Prenetics and Veracyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are developed.
|
Detailed competitors of Natera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Natera
Complete news archive for Natera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Natera
Natera was founded in 2004 and raised its 1st funding round 2 years after it was founded.
Natera is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Natera is a funded company, having raised a total of $152.1M across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Natera is 4,430.
Annual revenue of Natera is $1.7B as on Dec 31, 2024.
Developer of cell-free DNA testing for oncology, womens health, and organ health. The test provided by the company inlcude Signatera a residual disease test (MRD), Altera tumor genomic profile, Empower Hereditary cancer test, Prospera Kidney transplant assessment, Panorama Noninvasive prenatal testing (NIPT), Anora Miscarriage Test, and more.
Natera's top competitors include Guardant Health, Exact Sciences and Foundation Medicine.
Natera offers Signatera, Panorama, Prospera, Horizon, and Renasight.
Yes, Natera is publicly traded on NASDAQ under the ticker symbol NTRA.
Natera has made 1 acquisition, including Foresight Diagnostics.
Natera has 15 investors. Key investors include Lightspeed Venture Partners, Franklin Templeton, HHS, Orbimed, and RA Capital.
The ticker symbol of Natera is NTRA on NASDAQ.